Enveric Biosciences reports Q4 2023 net loss of $3.44M; selects EB-003, signs out-licensing term sheets

Enveric Biosciences, Inc.

Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.
Selected EB-003 as lead neuroplastogen candidate for depression/anxiety without hallucinations.
Signed non-binding term sheets to out-license three compound classes (up to $200M milestones) and cannabinoid conjugates (up to $61M).
Completed warrant inducement exercises raising ~$4.5M gross proceeds.
Advanced IND-enabling studies for EB-002 including toxicology and safety pharmacology.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enveric Biosciences, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: net income $3.44 million for the fourth quarter ended December 31, 2023, EPS $1.46.

Period: fourth quarter and fiscal year ended December 31, 2023
Net income: $3.44 million for the fourth quarter ended December 31, 2023
EPS: $1.46
Result: reported results

Exact text from the filing

Net loss attributable to stockholders was $3.44 million for the fourth quarter ended December 31, 2023, including $1.48 million in net non-cash expense, with a basic and diluted loss per share of $1.46, as compared to a net loss of $8.80 million, including $4.48 million in net non-cash expense, with a basic and diluted loss per share of $4.89 for the quarter ended December 31, 2022.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.